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Abstract
Background: Next Generation Sequencing (NGS) of whole exomes or genomes is increasingly being used in
human genetic research and diagnostics. Sharing NGS data with third parties can help physicians and researchers
to identify causative or predisposing mutations for a specific sample of interest more efficiently. In many cases,
however, the exchange of such data may collide with data privacy regulations. GrabBlur is a newly developed tool
to aggregate and share NGS-derived single nucleotide variant (SNV) data in a public database, keeping individual
samples unidentifiable. In contrast to other currently existing SNV databases, GrabBlur includes phenotypic
information and contact details of the submitter of a given database entry. By means of GrabBlur human
geneticists can securely and easily share SNV data from resequencing projects. GrabBlur can ease the interpretation
of SNV data by offering basic annotations, genotype frequencies and in particular phenotypic information - given
that this information was shared - for the SNV of interest.
Tool description: GrabBlur facilitates the combination of phenotypic and NGS data (VCF files) via a local interface
or command line operations. Data submissions may include HPO (Human Phenotype Ontology) terms, other trait
descriptions, NGS technology information and the identity of the submitter. Most of this information is optional
and its provision at the discretion of the submitter. Upon initial intake, GrabBlur merges and aggregates all sample-
specific data. If a certain SNV is rare, the sample-specific information is replaced with the submitter identity.
Generally, all data in GrabBlur are highly aggregated so that they can be shared with others while ensuring
maximum privacy. Thus, it is impossible to reconstruct complete exomes or genomes from the database or to re-
identify single individuals. After the individual information has been sufficiently “blurred”, the data can be uploaded
into a publicly accessible domain where aggregated genotypes are provided alongside phenotypic information. A
web interface allows querying the database and the extraction of gene-wise SNV information. If an interesting SNV
is found, the interrogator can get in contact with the submitter to exchange further information on the carrier and
clarify, for example, whether the latter’s phenotype matches with phenotype of their own patient.
Background
Since the introduction in 2005, Next Generation DNA
Sequencing (NGS) has been used successfully in numerous
research projects [1]. Meanwhile, further technological
advances have reduced the per base pair sequencing costs
dramatically, thereby allowing more and more molecular
diagnostics laboratories to screen the complete exome of
individual patients with an apparently inherited disease for
causative mutations [2]. Indeed, exome sequencing has
already started to revolutionize diagnostic genetic testing
[3][4]. However, pertinent data privacy law, the type of
informed consent declarations used and limited genetic
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counseling resources bar sharing of high-resolution
genetic data with third parties in most countries. From
both a medical and a scientific point of view, this “locking”
of data is hardly compatible with good professional prac-
tice. For instance, for a physician or geneticist it may be
essential to know whether a particular mutation found in
the genome of their patient has been found in another
patient with a similar phenotype before. Related questions
are also likely to arise in basic research projects on both
monogenic and complex (i.e. oliogenetic) diseases.
Tool description
We developed GrabBlur, a tool to collect and aggregate
(i.e. “grab” and “blur”) ‘single nucleotide variants’ (SNVs)
linked to a specific trait or phenotype, and to share them
with others by way of a public database while keeping
individual samples unidentifiable. The database will not
only help human geneticists to distinguish between
benign variant findings and truly disease-causing muta-
tions, but will also benefit genetic epidemiological
research (i.e. case-control association studies) based upon
large-scale SNV data.
In contrast to databases like ClinVar (http://www.ncbi.
nlm.nih.gov/clinvar/) or the Human Gene Mutation
Database (HGMD) [5], which only contain out-of-context
information on genotype-phenotype associations, Grab-
Blur provides access to all SNVs detected in a given
patient alongside the description of their specific pheno-
type. The Exome Variant Server (EVS) [6] provides about
2 million annotated SNVs of 6,500 individuals with
heart-, lung- and blood-related diseases; more details are
not specified. Through the straightforward aggregation of
SNVs, it is not possible to find out, which SNV originated
from which individual and phenotype. The EVS helps
researchers excluding SNV candidates found in patients
with monogenetic diseases, but it is not a resource to
exchange genotypic and phenotypic data from other data
sets, especially for Mendelian diseases where often the
exact phenotypes are needed. Owing to this level of com-
prehensiveness, GrabBlur helps users not only to reckon
known mutations, but also to validate newly found ones.
The most important feature of GrabBlur is the high
level of anonymity ensured by its process of data aggrega-
tion. No conclusions as to the identity of a patient can be
drawn even if the entire data stored for that individual
are downloaded or the whole database is mirrored. It is
possible neither to reconstruct a single patient genome
nor to re-identify a patient from knowing their SNVs.
Data is aggregated at the site of the submitter, i.e. behind
their own firewall and under their responsibility for data
protection. Hence, no identifying data leaves the submit-
ter institution, and even if the data is “tapped” by an
unauthorized person during upload to the database, a
high level of privacy protection is maintained.
DNA sequence data are accepted by GrabBlur in stan-
dardized VCF format [7]. Additional information such as
the phenotype or gender of a patient is stored in a separate
“initialization file” (INI file format). Most of this informa-
tion is optional and provision is at the discretion of the
submitter. The following information may be recorded:
• Trait. A description of the disease of all patients in
a GrabBlur set of samples (see below). Samples must
be marked at least as ‘patient’ or ‘healthy control’.
(mandatory)
• Phenotype: GrabBlur uses Human Phenotype
Ontology (HPO) terms [8] to classify phenotypes.
Every phenotype can be ascribed an unlimited num-
ber of HPO terms. (optional)
• Gender: Gender of a single patient. (optional)
• Platform: DNA sequencing technology used.
(optional)
• Enrichment: DNA enrichment kit used for
sequencing. (optional)
• PI: Identity of principal investigator. (optional)
• Contact details: Identity, affiliation and e-mail
address of the submitter (mandatory for upload, but
optional release to public database)
To help users with the creation of the initialization
file, we developed a web interface (Figure 1) to com-
fortably enter the required information, including
sample ID and phenotype description. Although Grab-
Blur encodes phenotypes by a combination of HPO
terms, users do not have to translate symptoms into
numeric IDs. Instead, we employ an auto-completion
procedure that finds all HPO terms matching the user
input. The chosen terms are then presented in a tree
structure, with their definitions accompanied by par-
ent and children terms. This allows users to easily
refine their description by choosing a more eligible
term. In addition to marking symptoms as present,
users can also identify particular symptoms as being
absent to accentuate interesting characteristics of their
patient.
On the project homepage, we also provide Perl scripts
to read either a single VCF file or all VCF files con-
tained in one directory and to directly submit filenames
and sample IDs to this interface.
GrabBlur aggregates data in the following three steps:
1. Inspection of the additional information avail-
able for every patient
To prevent identification of a patient via the combina-
tion of different individual-specific informational items,
these items must not be unique in the set of sample data
provided to a third party. Every variant of a patient is asso-
ciated with his meta-data. In case of uniqueness, the
reconstruction of a patient’s genome would be possible. At
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least two samples must have exactly the same phenotypes,
same gender information etc.
In order to generate a sufficient level of ambiguity,
samples with an identical set of HPO terms are combined
in classes. If any other additional information is not suffi-
ciently ambiguous, GrabBlur blurs it by deleting e.g. the
gender or the platform-name.
2. Fragmentation of the SNV-data
In a second step, the SNVs of a sample are divided into
sub-samples of different size. A list linking sample IDs and
sub-sample IDs is stored in a encrypted and password-
protected file at the submitter site. Encryption is accom-
plished by means of the Blowfish algorithm of OpenSSL
[9]. Only the submitter themselves can open this file. This
is needed, for example, to delete a sample from the data-
base in case the patient withdraws the consent.
Each SNV of a sample is randomly assigned to a sub-
sample. This assignment is not uniformly distributed
because otherwise any group of linked sub-samples would
contain an approximately equal number of SNVs, thereby
allowing reconstruction of the complete sample. Therefore
SNVs are assigned to a sub-sample with a differently
weighted likelihood.
3. Blurring the genotype information for rare variants
In a third step, all rare variants of a sample are aggre-
gated by replacing the sub-sample ID of a rare SNV by
the contact information of the submitting institution.
Since a patient can easily be identified by singletons (i.e.
SNVs that have been detected only once), these and
other rare SNVs in their exome are blurred. In the
aggregation step the association between an SNV and all
belonging sub-samples has been deleted. Only the trait
and (if known) the submitting institution remain linked
to the SNV. Hence, only common SNVs carry a sub-
sample ID and, therefore, are associated with specific
phenotype information.
The threshold for a variant to be considered rare is
variable and depends upon the submitted data. It is cal-
culated from the median of all SNV frequencies as
freq(SNV) =< 1.5 ∗med(frq)
Here, freq(SNV) denotes the frequency of the SNV
irrespective of its genotype, and med(frq) is the median
over all SNV frequencies in the sample set. We choose
the median because it is robust against outliers, like in
this case above-average number of singletons.
The default factor of 1.5 can be modified by the sub-
mitter to get a lower or higher aggregation level.
Usually, with a default factor of 1.5, the threshold equals
between 8 and 12 so that a data set must comprise at
least 8 to 12 samples in order to provide additional
information other than the contact address.
Figure 1 Creation of the initialization file. Screenshot of the interface to create the initialization files. The auto-completion procedure finds all
HPO terms matching the user input. The chosen terms are then presented in a tree structure, with their definitions accompanied by parent and
children terms.
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Figure 2 shows the ratio of unblurred data (SNVs
where the genotype is not aggregated) in relationship to
the amount of aggregated samples using the default med-
ian factor of 1.5. The part of unblurred data increases
logarithmically to the number of aggregated samples.
Through the blurring of the rare variants the portion of
unblurred data is reaching a plateau of about 70%.
Hence, a good minimum sample size is n = 100 so that as
less genotype information as possible gets blurred.
Figure 3 shows the frequency distribution of a sample
set containing 50 randomly chosen exomes. As expected,
the proportion of singletons is 10 times higher than that
of common SNVs. In the given example, the threshold
frequency for rare variants would be approximately 20%
(or 10 occurrences).
Aggregation quality
To assess the aggregation quality and hence the level of
ensured anonymity, a sample set of 10 individuals was
blurred and compared to one randomly selected and non-
aggregated sample of that set. For illustration, the sub-
samples in Figure 4 were sorted according to the original
sample IDs (sample ID, sub-sample ID on the X-axis). The
selected individual is sample no. 6. It turns out that the
overlap between a sample and its matching sub-samples is
not notably larger than with other sub-samples. This is
important if the data upload is intercepted or if the data-
base itself gets compromised. Moreover, the aggregation
also makes it impossible for an interested authority to
identify an individual by comparing their own genetic data
to the GrabBlur database (e.g. a law enforcement authority
searching for a suspect).
Data access
After the aggregation steps, the blurred data is written
into a new VCF file at the submitter site (Figure 5) from
where they are being uploaded to the public database.
This process does not start automatically so that the
submitter keeps control of the data they provide. After
uploading, other registered users are able to retrieve
information on the submitted SNVs and their associated
phenotypes. To access the GrabBlur database, we devel-
oped a web front end (accessible at http://grabblur.
ikmb.uni-kiel.de) that offers two main features:
(1) After registration, users can upload their data. The
web front end allows the user to choose an aggregated
VCF-file, which must have been created before using
the blurring software described above. The front end
sends the file to a client software running on the same
server, which checks the file for consistency and poten-
tial corruptions and then transfers it to the database.
During the upload-process, every SNV is automatically
functionally annotated using our in-house software tool
snpActs (http://snpacts.ikmb.uni-kiel.de). snpActs identifies
whether an SNV causes a protein coding substitution and
which amino acid is affected using the gene annotations
Figure 2 Ratio of the unblurred data with various sample set sizes. The ratio of unblurred data (SNVs where the genotype is not
aggregated) in relationship to the amount of aggregated samples using the default median factor of 1.5. The part of unblurred data increases
logarithmically to the number of aggregated samples. Through the blurring of the rare variants the portion of unblurred data is reaching a
plateau of about 70%. Hence, a good minimum sample size is n = 100 so that as less genotype information as possible gets blurred. For blurred
SNVs no genotype will be notified, only the contact data of the submitter will be named.
Stade et al. BMC Genomics 2014, 15(Suppl 4):S8
http://www.biomedcentral.com/1471-2164/15/S4/S8
Page 4 of 8
from CCDS [10] and RefSeq [11]. The amino acid
changes in all iso-forms of the affected gene are classified
and ranked in the following order: “nonsense” (most likely
to be damaging), “readthrough”, “start-lost”, “splice site”,
“missense”, “synonymous” (least likely to be damaging).
To obtain more information for estimating whether an
SNV is likely to be damaging, snpActs also queries the
Human Gene Mutation Database “HGMD” [5]. HGMD
provides a database of comprehensive, in part manually
curated data on human inherited disease mutations. Since
this is a commercially available database, only an identi-
fier from the HGMD database is named in snpActs. All
results of these annotations, including the highest ranked
classification of the SNV, are stored in the database upon
upload of the data.
(2) All registered users are able to search the database
for loci of interest using either the chromosomal position,
the dbSNP IDs of known SNVs, gene symbols, or a protein
position in combination with a gene symbol. The latter is
particularly useful to identify potentially compound het-
erozygote samples. However, phase information needs to
be retrieved from the submitter via re-contact. Registered
users can also perform combined searches simultaneously
looking for terms of different type (e.g. “chr1:13272” and
“rs6605067” and “NOD2”), so the search result contains
information about the locus, i.e. weather it is situated
within a gene, the gene identifier and gene function, and
how many samples in the database carry an SNV at this
locus (Figure 6). The allele and genotype frequencies of
every SNV over all samples in the database are displayed
as well as publicly available allele frequencies from the
1000 Genomes Project [12] (phase1) and from the Exome
Variant Project [6] (ESP6500SI-V2). The user can access
further information for each of these sets of samples, if
provided by the submitter, including the associated trait in
the form of HPO terms (Figure 7). Additional information,
like the submitter contact information or the sample gen-
der (Figure 8), can be obtained also if provided.
Implementation
The aggregation software was written in C++ on an
Ubuntu Linux system. The runtime of the aggregation
increases linearly with the amount of samples. The con-
sumption of memory (RAM) increases logarithmically. On
a desktop PC, a VCF file with 43,000 SNV was aggregated
in less than 3 seconds using one core (Intel Xeon 4C,
2.0GHz). The aggregation of 50 exomes with about 40,000
- 45,000 SNVs needs approximately 128 MB RAM and
130 sec. The aggregation of 150 exomes needs about
7 minutes with approximately 350 MB RAM.
Figure 3 SNV frequency distribution in a sample of 50 exomes. Evidently, the proportion of singletons is 10 times higher than that of
common SNVs. In the depicted example, the threshold frequency for rare variants was approximately 20% resp. 10 SNVs.
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The interface for the creation of the initialization files
is programmed in Perl and uses JavaScript and AJAX to
display the HPO terms retrieved from a PostgreSQL
database.
The web interface for data access has been implemen-
ted using the Django web application framework [13]
(v1.5.4) and the Python programming language [14]
(v3.2.2). It is currently running on an Ubuntu Linux
Figure 4 Assessment of the aggregation quality. To assess the aggregation quality of GrabBlur, a sample set of 10 individuals was “blurred”
and compared to a non-aggregated sample of that set. For illustration purposes, the sub-samples were sorted according to the original sample
IDs (sample ID, sub-sample ID on the X-axis). The corresponding individual is sample no. 6. The overlap between the sub-samples originating
from this sample is not significantly higher than with the other samples.
Figure 5 Output file “aggregated VCF”. GrabBlur writes the aggregated SNV data of all samples into a new VCF file. This figure shows a
typical GrabBlur output of blurred SNVs. Some VCF information has been excluded, such as the dbSNP-ID and quality information, for
explanatory purposes.
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Server (12.04.3 LTS). The MySQL database containing
the actual GrabBlur data is located on another server
(with the same configuration) and is accessed using the
respective built-in modules of Django and Python.
Discussion
GrabBlur is a “light weight” tool to aggregate SNV data of
thousands of samples with a specific trait or phenotype
and to share the data with other via a public database.
The main goal of GrabBlur, namely to keep each indivi-
dual sample unidentifiable, was achieved by deleting
other important information from individual exomes or
genomes. For instance, all information of linked SNVs
must be dropped to avoid the reconstruction of a given
data set. But exactly this information is very valuable for
scientific studies. For example, rare variant association
analysis methods collapse rare variants into groups based
upon, for example, the functional annotation of genomic
regions. Whether GrabBlur can be used in such studies
needs to be verified individually for each analysis method
(for a review of methods, see [15]). However, GrabBlur is
intended mainly to serve human geneticists who try to
find more data on a variant and the phenotype of inter-
est. The user-friendly GrabBlur web interface should
inspire users to share their data and to use the tool for
their own purposes. Although GrabBlur anonymizes the
genetic data to a sufficient degree, a cautious user may
want to use GrabBlur only behind their own firewall to
handle aggregated information. While we encourage
users to share their data, we also support such “internal”
mirrors and provide instructions to set them up.
GrabBlur also has limitations that should not go unmen-
tioned. For example, the system is not yet checking for
duplicate uploads. It is thus possible that redundant data
end up in the GrabBlur database. Moreover, the quality of
an uploaded SNV may not have been adequately checked.
Detailed quality data, as it can be generated using our pre-
viously reported tool pibase [16], would require that users
also retrieve BAM files for their sequence data, run addi-
tional and standardized analyses. Moreover, the addition
of the quality scores would significantly inflate the Grab-
Blur database. We rather prefer that submitter provide
their contact details so that data users can enquire the
quality of particular SNVs directly. The submitter may
then go back to the raw data and use pibase, the Inte-
grated Genomics Viewer [17] or other tools to assess the
quality of the SNV in more detail. It is also possible with
GrabBlur to ask submitters for additional details on the
phenotype of a patient or for a detailed re-phenotyping
based on new scientific findings.
Figure 6 Web front end - search results. The figure shows an example search result for selected loci. The latter does not lie within a gene, so
no additional gene information is provided. For the other two search terms the in-silico predicted gene function and effect of the SNV on the
gene are provided. For all loci the number of samples in database with known genotype information is given - along with the frequencies for
the genotypes and just the alleles.
Figure 7 Web front end - samples associated with one locus. This view of the front end gives detailed information about the samples
associated with one particular locus including the actual genotype, the trait (as an user definable term) and the HPO ID and terms as they were
determined during the creation of the upload file.
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Figure 8 Web front end - sample details. In addition to the sample list (Figure 7) this detailed view provides the sex of the sample and the
contact information provided by the uploader to get more information on the sample.
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